Trial Outcomes & Findings for Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor (NCT NCT00028002)

Last Updated: 2020-10-26

Results Overview

Kaplan-Meier estimate of disease progression rate. Disease progression is determined by Response Evaluation Criteria in Solid Tumours criteria (RECIST). RECIST criteria is described here: http://ctep.cancer.gov/protocolDevelopment/docs/recist\_guideline.pdf

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

63 participants

Primary outcome timeframe

From registration to two years

Results posted on

2020-10-26

Participant Flow

Participant milestones

Participant milestones
Measure	Imatinib Mesylate Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years.
Overall Study STARTED	63
Overall Study COMPLETED	52
Overall Study NOT COMPLETED	11

Reasons for withdrawal

Reasons for withdrawal
Measure	Imatinib Mesylate Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years.
Overall Study Withdrawal by Subject	3
Overall Study Ineligible	8

Baseline Characteristics

Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Imatinib Mesylate n=52 Participants Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years.
Age, Continuous	58.5 years n=5 Participants
Sex: Female, Male Female	24 Participants n=5 Participants
Sex: Female, Male Male	28 Participants n=5 Participants

PRIMARY outcome

Timeframe: From registration to two years

Population: All eligible patients.

Outcome measures

Outcome measures
Measure	Imatinib Mesylate n=52 Participants Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years.
Rate of Disease Progression at 2 Years	13.8 percentage of participants Interval 4.2 to 23.4

SECONDARY outcome

Timeframe: Pretreatment and prior to surgery (at 4-10 weeks, based on surgery timing)

Population: Eligible patients who started study treatment

The percentage of patients who achieved a complete, partial or stable response prior to surgery as assessed by Response Evaluation Criteria in Solid Tumours criteria (RECIST). RECIST criteria is described here: http://ctep.cancer.gov/protocolDevelopment/docs/recist\_guideline.pdf.

Outcome measures

Outcome measures
Measure	Imatinib Mesylate n=52 Participants Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years.
Rates of Objective Response (Complete, Partial, and Stable) Complete Response	0 percentage of participants Interval 0.0 to 0.0
Rates of Objective Response (Complete, Partial, and Stable) Partial Response	5.8 percentage of participants Interval 1.2 to 15.9
Rates of Objective Response (Complete, Partial, and Stable) Stable Disease	86.5 percentage of participants Interval 74.2 to 94.4

SECONDARY outcome

Timeframe: Analysis occurs after all patients have been on study for at least 2 years. Measured from start of treatment to end of follow-up, to a maximum of 4.95 years.

Population: All eligible patients who started study treatment (for pre-surgery), and who additionally had surgery (post-surgery)

Highest grade toxicity per subject was counted. Toxicities were graded using Common Toxicity Criteria (CTC) v 2.0. Grade refers to the severity of the toxicity, using Grades 1 through 5 with unique clinical descriptions of severity for a given toxicity based on this general guideline: Grade 1 Mild, Grade 2 Moderate, Grade 3 Severe, Grade 4 Life-threatening or disabling, Grade 5 Death related to toxicity.

Outcome measures

Outcome measures
Measure	Imatinib Mesylate n=52 Participants Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years.
Percentage of Patients With Major Toxicity (Toxicity Grade ≥ 3) Pre-surgery	34.6 percentage of participants Interval 22.0 to 49.1
Percentage of Patients With Major Toxicity (Toxicity Grade ≥ 3) Post-surgery	48.9 percentage of participants Interval 33.7 to 64.2

SECONDARY outcome

Timeframe: change from baseline to 1 week post therapy

evaluate FDG-PET as a non-invasive functional imaging tool to assess in situ tumor metabolism (as measured by the Standardized Uptake Values of FDG in the tumor) prior to and during the administration of IM. %change in SUVmax \<1 indicate decreased tumor metabolism while values \>1 indicated an increase in tumor metabolism. Metabolic response by 18F-FDG PET was determined in accordance with the criteria of the European Organization for Research and Treatment of Cancer EORTC), with increases or decreases of more than 25% in SUVmax defining progressive metabolic disease (PMD) and partial metabolic response (PMR), respectively, and new lesions defining PMD.

Outcome measures

Outcome measures
Measure	Imatinib Mesylate n=44 Participants Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years.
FDG-PET as Biological Marker of Metabolic Response(MR) During Imatinib Mesylate (IM) Treatment, in Patients With GIST Who Are naı¨ve to Tyrosine Kinase Inhibitor Therapy	-59.4 percentage change in SUVmax Interval -100.0 to 81.4

Adverse Events

Imatinib Mesylate

Serious events: 22 serious events

Other events: 52 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Imatinib Mesylate n=52 participants at risk Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years.
Blood and lymphatic system disorders Anemia	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Blood and lymphatic system disorders Febrile neutropenia	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Cardiac disorders Cardiac disorders - Other	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Gastrointestinal disorders Colitis	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Gastrointestinal disorders Esophageal fistula	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Gastrointestinal disorders Gastrointestinal disorders - Other	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Gastrointestinal disorders Upper gastrointestinal hemorrhage	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Gastrointestinal disorders Vomiting	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
General disorders Fever	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
General disorders General disorders and administration site conditions - Other	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Infections and infestations Infections and infestations - Other	9.6% 5/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Infections and infestations Wound infection	5.8% 3/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Investigations Neutrophil count decreased	7.7% 4/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Investigations Serum amylase increased	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Metabolism and nutrition disorders Anorexia	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Metabolism and nutrition disorders Hypocalcemia	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Metabolism and nutrition disorders Hyponatremia	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Nervous system disorders Dizziness	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Nervous system disorders Intracranial hemorrhage	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Nervous system disorders Peripheral motor neuropathy	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Respiratory, thoracic and mediastinal disorders Hypoxia	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Respiratory, thoracic and mediastinal disorders Pleural effusion	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Respiratory, thoracic and mediastinal disorders Pneumonitis	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Respiratory, thoracic and mediastinal disorders "Respiratory, thoracic and mediastinal disorders - Other"	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Vascular disorders Capillary leak syndrome	5.8% 3/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Vascular disorders Thromboembolic event	5.8% 3/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Vascular disorders Vascular disorders - Other	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.

Other adverse events

Other adverse events
Measure	Imatinib Mesylate n=52 participants at risk Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years.
Blood and lymphatic system disorders Anemia	84.6% 44/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Blood and lymphatic system disorders Blood and lymphatic system disorders - Other	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Blood and lymphatic system disorders Febrile neutropenia	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Cardiac disorders Cardiac disorders - Other	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Cardiac disorders Palpitations	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Cardiac disorders Pericardial effusion	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Cardiac disorders Sinus tachycardia	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Cardiac disorders Ventricular arrhythmia	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Ear and labyrinth disorders Ear and labyrinth disorders - Other	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Ear and labyrinth disorders Hearing impaired	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Endocrine disorders Hypothyroidism	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Eye disorders Blurred vision	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Eye disorders Conjunctivitis	7.7% 4/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Eye disorders Dry eye	5.8% 3/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Eye disorders Eye disorders - Other	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Eye disorders Watering eyes	19.2% 10/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Gastrointestinal disorders Abdominal pain	19.2% 10/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Gastrointestinal disorders Ascites	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Gastrointestinal disorders Constipation	15.4% 8/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Gastrointestinal disorders Diarrhea	55.8% 29/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Gastrointestinal disorders Dyspepsia	13.5% 7/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Gastrointestinal disorders Flatulence	9.6% 5/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Gastrointestinal disorders Gastric ulcer	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Gastrointestinal disorders Gastrointestinal disorders - Other	13.5% 7/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Gastrointestinal disorders Mucositis oral	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Gastrointestinal disorders Nausea	65.4% 34/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Gastrointestinal disorders Rectal hemorrhage	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Gastrointestinal disorders Rectal pain	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Gastrointestinal disorders Vomiting	32.7% 17/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
General disorders Chills	5.8% 3/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
General disorders Fatigue	38.5% 20/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
General disorders Fever	13.5% 7/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
General disorders Non-cardiac chest pain	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
General disorders Pain	23.1% 12/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Hepatobiliary disorders Hepatobiliary disorders - Other	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Immune system disorders Immune system disorders - Other	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Infections and infestations Infections and infestations - Other	15.4% 8/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Infections and infestations Wound infection	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Injury, poisoning and procedural complications Intraoperative venous injury	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Injury, poisoning and procedural complications Wound dehiscence	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Investigations Alanine aminotransferase increased	21.2% 11/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Investigations Alkaline phosphatase increased	21.2% 11/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Investigations Aspartate aminotransferase increased	32.7% 17/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Investigations Blood bilirubin increased	17.3% 9/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Investigations Cholesterol high	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Investigations Creatinine increased	11.5% 6/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Investigations Investigations - Other	9.6% 5/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Investigations Lymphocyte count decreased	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Investigations Neutrophil count decreased	40.4% 21/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Investigations Platelet count decreased	28.8% 15/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Investigations Serum amylase increased	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Investigations Weight gain	11.5% 6/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Investigations Weight loss	15.4% 8/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Investigations White blood cell decreased	50.0% 26/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Metabolism and nutrition disorders Acidosis	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Metabolism and nutrition disorders Anorexia	11.5% 6/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Metabolism and nutrition disorders Dehydration	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Metabolism and nutrition disorders Hypercalcemia	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Metabolism and nutrition disorders Hyperglycemia	44.2% 23/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Metabolism and nutrition disorders Hyperkalemia	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Metabolism and nutrition disorders Hypermagnesemia	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Metabolism and nutrition disorders Hypernatremia	5.8% 3/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Metabolism and nutrition disorders Hypertriglyceridemia	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Metabolism and nutrition disorders Hypoalbuminemia	21.2% 11/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Metabolism and nutrition disorders Hypocalcemia	23.1% 12/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Metabolism and nutrition disorders Hypoglycemia	7.7% 4/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Metabolism and nutrition disorders Hypokalemia	25.0% 13/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Metabolism and nutrition disorders Hypomagnesemia	9.6% 5/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Metabolism and nutrition disorders Hyponatremia	11.5% 6/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Metabolism and nutrition disorders Hypophosphatemia	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Musculoskeletal and connective tissue disorders Arthralgia	7.7% 4/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Musculoskeletal and connective tissue disorders Bone pain	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Musculoskeletal and connective tissue disorders Generalized muscle weakness	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Musculoskeletal and connective tissue disorders Myalgia	28.8% 15/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumor pain	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Nervous system disorders Dizziness	7.7% 4/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Nervous system disorders Dysgeusia	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Nervous system disorders Headache	5.8% 3/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Nervous system disorders Peripheral sensory neuropathy	9.6% 5/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Nervous system disorders Vasovagal reaction	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Psychiatric disorders Anxiety	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Psychiatric disorders Confusion	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Psychiatric disorders Depression	5.8% 3/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Psychiatric disorders Insomnia	5.8% 3/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Renal and urinary disorders Renal and urinary disorders - Other	5.8% 3/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Renal and urinary disorders Urinary frequency	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Renal and urinary disorders Urinary incontinence	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Renal and urinary disorders Urinary tract pain	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Reproductive system and breast disorders Gynecomastia	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Reproductive system and breast disorders Pelvic pain	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Reproductive system and breast disorders Reproductive system and breast disorders - Other	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Respiratory, thoracic and mediastinal disorders Allergic rhinitis	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Respiratory, thoracic and mediastinal disorders Cough	15.4% 8/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Respiratory, thoracic and mediastinal disorders Dyspnea	11.5% 6/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Respiratory, thoracic and mediastinal disorders Epistaxis	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Respiratory, thoracic and mediastinal disorders Hiccups	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Respiratory, thoracic and mediastinal disorders Pleural effusion	15.4% 8/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Respiratory, thoracic and mediastinal disorders Pleuritic pain	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Respiratory, thoracic and mediastinal disorders Pneumonitis	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Skin and subcutaneous tissue disorders Alopecia	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Skin and subcutaneous tissue disorders Dry skin	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Skin and subcutaneous tissue disorders Nail loss	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Skin and subcutaneous tissue disorders Pruritus	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Skin and subcutaneous tissue disorders Rash maculo-papular	34.6% 18/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Skin and subcutaneous tissue disorders Skin and subcutaneous tissue disorders - Other	3.8% 2/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Vascular disorders Capillary leak syndrome	53.8% 28/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Vascular disorders Flushing	1.9% 1/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Vascular disorders Hot flashes	5.8% 3/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Vascular disorders Hypertension	7.7% 4/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Vascular disorders Lymphedema	5.8% 3/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.
Vascular disorders Vascular disorders - Other	5.8% 3/52 • Adverse event (AE) information is collected Weeks 1, 4, 8, Months 3,8,9, then every 3 months until 2 years, then every 6 months until 5 years, then annually. (SAE = Serious Adverse Event). Per the protocol, toxicity data was collected via CTC 2.0 then mapped to CTCAE 4.0 to report here. Subjects experiencing more than one of a given adverse event (AE) are counted only once for that AE.

Additional Information

Wendy Seiferheld

Radiation Therapy Oncology Group

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Restriction type: LTE60